Volume 21 Issue 7
Jul.  2023
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2023  >  21(7): 1150-1152
LI Chengbiao, GU Gangshou. Efficacy of anlotinib in the third-line treatment of advanced ovarian cancer[J]. Chinese Journal of General Practice, 2023, 21(7): 1150-1152. doi: 10.16766/j.cnki.issn.1674-4152.003071
Citation: LI Chengbiao, GU Gangshou. Efficacy of anlotinib in the third-line treatment of advanced ovarian cancer[J]. Chinese Journal of General Practice, 2023, 21(7): 1150-1152. doi: 10.16766/j.cnki.issn.1674-4152.003071
shu

Efficacy of anlotinib in the third-line treatment of advanced ovarian cancer

doi: 10.16766/j.cnki.issn.1674-4152.003071

  • Department of Medical Oncology, Wuwei People's Hospital, Wuwei, Gansu 733000, China

Funds:

 20JR10RA779

  • Received Date: 2022-12-07
    Available Online: 2023-08-28
    Abstract
  •   Objective  To observe the clinical efficacy and toxicity of anlotinib as a third-line treatment for advanced ovarian cancer, and to evaluate the clinical value of this treatment.  Methods  A total of 60 patients with advanced ovarian cancer who were treated in Wuwei People's Hospital from May 1, 2020 to April 30, 2022 were selected. The patients were divided into control group (n=30) and treatment group (n=30) by random number table method. The treatment group was treated with anlotinib as third-line treatment, and the control group was only given best supportive treatment. The objective response rate (ORR), disease control rate (DCR), quality of life (KPS score) and progression-free survival (PFS) of the two groups were compared. The side effects of anlotinib treatment were observed to evaluate the efficacy and safety of anlotinib.  Results  The ORR and DCR of the treatment group were 26.7% (8/30) and 86.7% (26/30), respectively. The ORR and DCR of the control group were 0 and 23.3% (7/30), respectively. There were significant differences in ORR and DCR between the two groups (both P<0.05). After treatment, the KPS score of the treatment group was (82.17±9.56) points, which was significantly higher than (75.18±9.15) points of the control group, and the difference was statistically significant (t=2.893, P=0.005). Some patients in the treatment group had nausea and vomiting, flatulence, diarrhea, fatigue, hypertension and loss of appetite during the treatment, but they could be tolerated and did not affect the treatment.  Conclusion  Anlotinib as a third-line treatment for advanced ovarian cancer has good short-term clinical efficacy and high safety.

     

    • FullText(HTML)
  • loading
    • References(17)
  • [1]
    孙玉莹, 段微. 循环肿瘤DNA在卵巢癌诊断和治疗中的应用[J]. 现代妇产科进展, 2022, 31(5): 397-400. https://www.cnki.com.cn/Article/CJFDTOTAL-XDFC202205019.htm

    SUN Y Y, DUAN W. Application of circulating tumor DNA in the diagnosis and treatment of ovarian cancer[J]. Progress in Obstetrics and Gynecology, 2022, 31(5): 397-400. https://www.cnki.com.cn/Article/CJFDTOTAL-XDFC202205019.htm
    [2]
    殷爱军, 李鹏, 宋坤, 等. 安罗替尼在妇科肿瘤治疗中的现状及研究进展[J]. 现代妇产科进展, 2022, 31(5): 384-388, 393. https://www.cnki.com.cn/Article/CJFDTOTAL-XDFC202205016.htm

    YIN A J, LI P, SONG K, et al. Current status and research progress of anlotinib in the treatment of gynecological tumors[J]. Progress in Obstetrics and Gynecology, 2022, 31(5): 384-388, 393. https://www.cnki.com.cn/Article/CJFDTOTAL-XDFC202205016.htm
    [3]
    崔广华, 杨宇. 安罗替尼在晚期恶性肿瘤治疗中的研究进展[J]. 现代肿瘤医学, 2022, 30(16): 3032-3036. doi: 10.3969/j.issn.1672-4992.2022.16.034

    CUI G H, YANG Y. Research progress of anlotinib in the treatment of advanced malignant tumors[J]. Journal of Modern Oncology, 2022, 30(16): 3032-3036. doi: 10.3969/j.issn.1672-4992.2022.16.034
    [4]
    陆富年, 张莉, 陈刚. 卵巢癌的分子诊断与靶向治疗[J]. 实用妇产科杂志, 2022, 38(8): 561-565. https://www.cnki.com.cn/Article/CJFDTOTAL-SFCZ202208001.htm

    LU F N, ZHANG L, CHEN G. Molecular diagnosis and targeted therapy of ovarian cancer[J]. Journal of Practical Obstetrics and Gynecology, 2022, 38(8): 561-565. https://www.cnki.com.cn/Article/CJFDTOTAL-SFCZ202208001.htm
    [5]
    郭钰, 徐鹏, 王蓓蒂, 等. 血清肿瘤标志物在卵巢癌诊断中的研究进展[J]. 中华全科医学, 2021, 19(8): 1362-1366. doi: 10.16766/j.cnki.issn.1674-4152.002061

    GUO Y, XU P, WANG B D, et al. The research progress of serum tumor markers in the diagnosis of ovarian cancer[J]. Chinese Journal of General Practice, 2021, 19(8): 1362-1366. doi: 10.16766/j.cnki.issn.1674-4152.002061
    [6]
    韩婷婷, 任艳, 刘明. 经阴道彩色多普勒超声检查卵巢癌患者血流指标与肿瘤恶性度和血管新生的关系[J]. 中国肿瘤临床与康复, 2021, 28(6): 699-703. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZK202106020.htm

    HAN T T, REN Y, LIU M. Relationship between transvaginal color Doppler ultrasound blood flow parameter and tumor malignancy and angiogenesis in patients with ovarian cancer[J]. Chinese Journal of Clinical Oncology and Rehabilitation, 2021, 28(6): 699-703. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZK202106020.htm
    [7]
    王娇, 门俊芬, 梁洪陆, 等. 安罗替尼治疗二线及以上化疗失败的铂耐药卵巢癌的疗效观察[J]. 保健文汇, 2022, 23(27): 97-100.

    WANG J, MEN J F, LIANG H L, et al. Efficacy of anlotinib in the treatment of platinum-resistant ovarian cancer after failure of second-line chemotherapy[J]. Chinese Journal of Health Care Literature, 2020, 23(27): 97-100.
    [8]
    夏婷婷. 安罗替尼治疗晚期卵巢癌对血清细胞凋亡分子和血管生成因子的影响[J]. 河北医药, 2021, 43(12): 1814-1817. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYZ202112012.htm

    XIA T T. Effects of anlotinib in treatment of advanced ovarian cancer on serum apoptosis molecules and angiogenic factors[J]. Hebei Medical Journal, 2021, 43(12): 1814-1817. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYZ202112012.htm
    [9]
    周琦, 吴小华, 刘继红, 等. 卵巢恶性肿瘤诊断与治疗指南(第四版)[J]. 中国实用妇科与产科杂志, 2018, 34(7): 739-749. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGSF201811011.htm

    ZHOU Q, WU X H, LIU J H, et al. Guidelines to the diagnosis and treatment of malignant ovary tumors(4th edition)[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2018, 34(7): 739-749. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGSF201811011.htm
    [10]
    李群, 徐鹏, 熊明. 中西医结合治疗对非小细胞肺癌患者疗效、毒副作用及KPS评分的影响[J]. 现代中西医结合杂志, 2019, 28(9): 991-993. https://www.cnki.com.cn/Article/CJFDTOTAL-XDJH201909023.htm

    LI Q, XU P, XIONG M. To investigate the effect of integrated traditional Chinese and western medicine treatment on the efficacy, toxic side effects and KPS score of patients with non-small cell lung cancer[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2019, 28(9): 991-993. https://www.cnki.com.cn/Article/CJFDTOTAL-XDJH201909023.htm
    [11]
    金惠敏, 林丽红, 赵振, 等. 安罗替尼联合PD-1抑制剂后线治疗晚期上皮性卵巢癌的疗效及安全性分析[J]. 肿瘤防治研究, 2022, 49(10): 1059-1064. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLFY202210008.htm

    JIN H M, LIN L H, ZHAO Z, et al. Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Advanced Epithelial Ovarian Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(10): 1059-1064. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLFY202210008.htm
    [12]
    唐清清, 莫月媚, 苏震朝, 等. 安罗替尼联合化疗治疗晚期恶性肿瘤的临床观察[J]. 中国处方药, 2021, 19(7): 4-6. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCF202107006.htm

    TANG Q Q, MO Y M, SU Z C, et al. Clinical observation of anlotinib combined with chemotherapy in the treatment of advanced malignant tumor[J]. Journal of China Prescription Drug, 2021, 19(7): 4-6. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCF202107006.htm
    [13]
    邱天竹, 周羽璇, 陈晓锋, 等. 安罗替尼三线及以上治疗晚期妇科肿瘤的临床观察[J]. 临床肿瘤学杂志, 2020, 25(11): 1018-1021. https://www.cnki.com.cn/Article/CJFDTOTAL-LCZL202011009.htm

    QIU T Z, ZHOU Y X, CHEN X F, et al. Efficacy and safety of anlotinib as the third-1ine and above therapy for metastatic gynecologic cancer[J]. Chinese Clinical Oncology, 2020, 25(11): 1018-1021. https://www.cnki.com.cn/Article/CJFDTOTAL-LCZL202011009.htm
    [14]
    杨雪晶, 宋东, 杨晓玲, 等. 盐酸安罗替尼治疗晚期恶性肿瘤的安全性及有效性分析[J]. 肿瘤研究与临床, 2020, 32(7): 489-492.

    YANG X J, SONG D, YANG X L, et al. Safety and efficacy analysis of anlotinib in treatment of advanced malignant tumors[J]. Cancer Research and Clinic, 2020, 32(7): 489-492.
    [15]
    陈倩, 赵秧, 康马飞, 等. 安罗替尼治疗多线化疗后进展晚期卵巢癌的疗效观察[J]. 中国实用医药, 2020, 15(7): 1-3. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA202007001.htm

    CHEN Q, ZHAO Y, KANG M F, et al. Efficacy observation of anlotinib in the treatment of advanced ovarian cancer after multi-line chemotherapy[J]. China Practical Medicine, 2020, 15(7): 1-3. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA202007001.htm
    [16]
    张秀芳, 陈萍. 安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效观察[J]. 医学信息, 2019, 32(18): 132-134, 137. https://www.cnki.com.cn/Article/CJFDTOTAL-YXXX201918044.htm

    ZHANG X F, CHEN P. Efficacy of anlotinib combined with cisplatin in the treatment of advanced ovarian cancer with malignant ascites[J]. Medical Informatics, 2019, 32(18): 132-134, 137. https://www.cnki.com.cn/Article/CJFDTOTAL-YXXX201918044.htm
    [17]
    李娜, 黄琦, 张明军, 等. 安罗替尼三线治疗晚期转移性结直肠癌疗效分析[J]. 中华医学杂志, 2019, 99(36): 2844-2847. https://cdmd.cnki.com.cn/Article/CDMD-10475-1020108008.htm

    LI N, HUANG Q, ZHANG M J, et al. Efficacy of anlotinib as a third-line treatment for advanced metastatic colorectal cancer[J]. National Medical Journal of China, 2019, 99(36): 2844-2847. https://cdmd.cnki.com.cn/Article/CDMD-10475-1020108008.htm
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (292) PDF downloads(5) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return